You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Biogen’s MS drug wins 15-year patent

Pill’s protection longer than expected

Federal officials Tuesday gave Biogen Idec Inc. 15-year patent protection for its multiple sclerosis pill Tecfidera, which is awaiting US regulatory approval.

The biotechnology company, based in Weston, said the US Patent Office granted a patent covering the 480-milligram daily dose for dimethyl fumarate, the active ingredient in Tecfidera, through 2028. That is the dosing amount sought in Biogen Idec’s new drug application, which the Food and Drug Administration is expected to rule on this month.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week